LabWare's kit includes a mobile hot spot and a tablet computer connected to a cloud-based Laboratory Information Management System software portal to capture patient demographic and clinical information, document field collection of respiratory swabs for COVID-19 testing, accession the sample, and rapidly disseminate this data to public health agencies.
In response to the COVID-19 pandemic, LabWare designed the Portable Disease Surveillance Lab kit to fit all the necessary components in a suitcase to enable patient registration and testing in field locations such as drive-up testing or assisted living facilities.
Patient demographics and triage details will be captured on the tablet computer, and the information will be transferred to the cloud.
With the addition of the Tangen testing system, high priority patient specimens will be tested immediately with Tangen's GeneSpark device, and both the patient details and test results will be transferred electronically through LabWare's cloud-based LIMS to public health labs and the CDC in less than 30 minutes.
The fast turnaround time should greatly improve surveillance programmes.
Beyond COVID-19, Tangen is making a Flu/COVID-19 Panel that can detect Flu A, Flu B and COVID-19 simultaneously from one patient sample in a single processing run, so that patients with flu-like symptoms will know whether they have flu or COVID-19 infection or none of them.
Tangen expects to continue its partnership with LabWare to include this multi-target testing.
The combination of Tangen's rapid, highly sensitive and point-of-care molecular diagnostics and LabWare's real-time data reporting LIMS software should enable public health systems to react quickly in terms of quarantine guidelines, patient tracing, hotspot monitoring, and infection surveillance.
Tangen's COVID-19 programme has been funded in part with Federal funds from the Department of Health and Human Services: Office of the Assistant secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00085.
Tangen Biosciences, Inc. was founded in 2013 and is located in Branford, Connecticut. The company developed the TangenDx platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rotary rapid isothermal nucleic acid detection.
The Tangen system consists of the TangenDx disc and the GeneSpark instrument, an automated amplification device.
The TangenDx platform, which does not require laboratory facilities, is expected to deliver faster, simpler, more sensitive detection at a lower cost than other commercial technologies.
Current tests in development include COVID-19, Candida auris, sepsis causing bacteria, antibiotic resistance genes, and a Candida blood panel.
The TangenDx platform is on track for infectious disease clinical studies.
LabWare is recognised as a leader of Laboratory Information Management Systems and instrument integration software products.
The company's Enterprise Laboratory Platform combines the award-winning LabWare LIMS and LabWare ELN, a comprehensive and fully integrated Electronic Laboratory Notebook application, which enables companies to optimise compliance, improve quality, increase productivity, and reduce costs.
LabWare Mobile is the newest addition to this platform, allowing users to interact with LabWare data on a mobile device using the device's native capabilities.
Founded in 1988, LabWare is headquartered in Wilmington, Delaware with offices located throughout the world to support customer installations in over 100 countries.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer